G2G ADVISORY

Chapter 16

The Healthcare Special

Pharma, MedTech, Services & Biotech — Models, Metrics & Valuation

Cram Sheet — Coming Soon Available on launch day

Deep dive into healthcare investment banking: from patent cliff quantification to pipeline rNPV valuation. Frameworks for London IB interviews and deal work across Big Pharma, Biotech, MedTech, Healthcare Services, CROs/CDMOs, Life Sciences Tools, and emerging genomics.

Chapter Roadmap

This chapter maps the healthcare sector as understood by London investment banking teams:

Big Pharma: Large integrated companies with patent protection, patent cliffs, and R&D-driven growth.
Specialty Pharma: Focused on niche therapies and rare diseases. Higher concentration risk.
Biotech: R&D companies developing novel therapies. High risk, high reward. Often pre-revenue or early-revenue.
Medical Devices / MedTech: Capital equipment + consumables. Razor/blade recurring revenue models.
Healthcare Services: Hospitals, clinics, diagnostic labs. Fee-for-service and capitated reimbursement.
Life Sciences Tools: Instruments, reagents, software for research. Recurring consumables.
CROs/CDMOs: Contract research and manufacturing. Fee-based, backlog-driven revenue.
Animal Health & Consumer Health: Veterinary and OTC segments with unique dynamics.
Genomics & Precision Medicine: Emerging segment. Early-stage, high valuation uncertainty.

PART I — FOUNDATIONS

Healthcare Metrics I

Pharma & Biotech Fundamentals

Revenue by Product / Franchise

Pharma companies report revenue by drug and therapy area. Track concentration: top drug as % of total revenue. Concentration >50% = high risk. Monitor each franchise for peak sales, current attach rate, and trend.

Patent Cliff / LOE (Loss of Exclusivity)

Date when generic or biosimilar competition can enter. The single biggest revenue risk in pharma. Revenue typically drops 70-90% within 2 years of small-molecule LOE. Biosimilars erode slower: 30-50% in year 1. Quantify revenue at risk by LOE date.

Pipeline Value

Present value of drugs in clinical development. Probability-weighted by stage: Preclinical ~5%, Phase I ~10%, Phase II ~15-20%, Phase III ~50-60%, Filed ~85-90%. Sum across all pipeline assets = pipeline rNPV.

Peak Sales Estimate

Projected maximum annual revenue for a drug at market maturity. Driven by addressable patient population, market penetration assumptions, and pricing. Critical input to pipeline valuation.

R&D Productivity

R&D spend ÷ number of drugs approved over a period. Industry average: $1-2B per approved drug. Declining productivity is a structural industry challenge.

Royalty Revenue

Income from licensing IP to other companies. Near 100% gross margin but declining as patents expire. Extract as a separate revenue stream in DCF.

Healthcare Metrics II

MedTech & Services Fundamentals

Organic Growth

Revenue growth excluding M&A and FX. MedTech organic growth typically 4-7% annually. Above 7% = exceptional. Threshold for premium valuation.

Procedure Volumes

Number of surgeries/procedures using the company's devices. Driven by demographics (aging), clinical adoption, and hospital budgets. Growth in volumes = operating leverage.

ASP (Average Selling Price)

Price per device/unit sold. Under constant pressure from hospital procurement consolidation (GPOs) and competitive intensity. ASP erosion = organic growth risk.

Installed Base & Razor/Blade Model

Capital equipment (the "razor") sold at low margin. Consumables and service contracts (the "blade") generate recurring high-margin revenue. Ratio of consumables/service to capital = quality of revenue.

Admissions / Bed Occupancy

For hospitals and healthcare services. Revenue = admissions × revenue per admission or bed occupancy × revenue per bed day. Key drivers of top-line growth.

Payer Mix

Percentage of revenue from private insurance, government (NHS/Medicare), self-pay. Private payer mix = higher reimbursement rates and margins. Track shift in mix as key operational driver.

Reimbursement Rate

The price that payers (NHS, insurers) will pay for a procedure or drug. Set by regulatory bodies (NICE in UK, CMS in US). Rate changes directly impact margin and volume demand.

Key Healthcare Formulas

Probability-Weighted Valuation & Pipeline Assessment

rNPV (Risk-Adjusted NPV) rNPV = Σ [PoS × ((Peak Sales × Market Share) × Years in Market) / (1 + r)^t - Costs] where PoS = probability of success by stage, r = discount rate (10-12%)

Pipeline Asset Value Asset Value = Peak Sales × PoS × NPV Factor (adjusted for time to market)

Patent Cliff Impact Cliff Risk = (Revenue at Risk / Total Revenue) × Expected Erosion % by Year

MedTech Recurring Revenue Ratio Recurring Ratio = (Consumables Revenue + Service Revenue) / Total Revenue Higher ratio = more predictable, lower growth optionality but stability

R&D Yield Yield = Peak Sales Potential of Approved Drugs / Cumulative R&D Spend

Worked Example: Pipeline rNPV

Scenario: Drug in Phase III, peak sales $3B, 55% PoS for Phase III, 8-year commercial life from launch, launch in 3 years, 10% discount rate.

Calculation: rNPV = 55% × PV($3B annuity for 8 years, discounted back 3 years at 10%) = 55% × $15.5B = ~$8.5B

Interpretation: This asset is worth ~$8.5B to the company in expected value terms, accounting for execution risk.

PART II — SUB-SECTOR DEEP DIVES

Big Pharma

Integrated Drug Development & Marketing

Business Model: Discover, develop, manufacture, and market patented drugs. Revenue from branded pharmaceuticals with patent protection (typically 10-15 years from filing).

Key Players: AstraZeneca, GSK, Novartis, Roche, Pfizer, J&J, Merck, Sanofi.

Margin Structure

Gross margin 70-80%, EBITDA margin 30-40%. R&D spend 15-20% of revenue. SG&A 25-30% (large sales forces for branded marketing).

Revenue Model

Drug sales + royalties + licensing income. Revenue concentration: top 5 drugs often 40-60% of revenue. Identifies key risks.

Patent Cliff Management

The existential challenge. Companies must: develop new drugs internally (R&D), acquire drugs/companies (M&A), or extend franchise life (new indications, formulations, combinations). Failure to manage cliff = secular revenue decline.

Geographic Diversification

US typically 40-50% of revenue (highest pricing), Europe 20-25%, Japan 5-10%, rest of world 15-25%. Pricing power varies by region. US IRA impact = margin pressure.

Big Pharma — Pipeline & Patent Cliffs

Managing Secular Decline through Innovation

Pipeline Stages: Preclinical → Phase I (safety) → Phase II (efficacy) → Phase III (efficacy at scale) → Regulatory Filing → Approval → Launch.

Attrition Rates

Only ~10% of Phase I drugs reach approval. Phase III is the most expensive ($100M-500M per trial) and riskiest. Attrition rates by stage: Phase I→II ~30%, Phase II→III ~25%, Phase III→Approval ~60%.

Patent Cliff Quantification

List each major drug, its current revenue, LOE date, and expected revenue erosion. Sum = total revenue at risk. Critical for DCF: project year-by-year erosion.

Biosimilar Competition

Biologic drugs face biosimilar competition post-patent. Erosion slower than small-molecule generics: 30-50% revenue loss in year 1 vs 70-90% for generics. Biosimilars are harder to manufacture and administer.

Life Cycle Management

Extend patent life and revenue: new indications (expand label), new formulations (extended-release), combination products (with other drugs), paediatric extensions (add 6 months exclusivity).

Pipeline Probability-Weighting

Value each asset by stage, peak sales estimate, time-to-market, and PoS by stage. Sum = total pipeline rNPV. This replaces cash cow revenue decline in valuation.

Key Risk A large patent cliff (>30% of revenue at risk in next 5 years) with no offsetting Phase III pipeline = secular decline in cash flows. Valuation must assume acquisitions or productivity improvements to offset.

Specialty Pharma

Focused Portfolios, Niche Indications

Definition: Focused on specific therapeutic areas or niche patient populations. Smaller scale than big pharma, often with fewer but higher-value drugs.

Business Model

Often relies on in-licensing or acquiring drugs from biotech, then commercialising with own sales force. Higher growth potential but higher concentration risk: 1-3 drugs may represent 80%+ of revenue.

Orphan Drugs

Treatments for rare diseases (<200K patients in US). Orphan drug designation provides: 7-10 year market exclusivity, tax credits, regulatory fast-track. Higher pricing accepted due to small patient population. Recombivax (hepatitis B vaccine) priced at $1k+ per dose.

Key Valuation Consideration

Patent cliff is even more acute for specialty pharma (fewer drugs to offset). Loss of one major drug = material revenue decline. Stress-test scenarios for key drug losses.

Specialty Pharma Example

Company with 3 drugs: Drug A ($800M, LOE in 4 years), Drug B ($300M, LOE in 7 years), Drug C ($200M, LOE in 2 years). Total revenue ~$1.3B. Revenue at risk in 5 years assuming 80% cliff = $800M + $200M = $1B cliff (77% of revenue). This company must have Phase III assets worth >$10B rNPV to offset.

Biotech

R&D-Focused, High Risk, High Reward

Business Model: R&D-focused companies developing novel therapies. Many are pre-revenue or early-revenue. High risk, high reward.

Revenue Model

Either commercialising own drugs or partnering/licensing to big pharma. Revenue = upfront payments + milestone payments + royalties (5-15% of net sales). Limited revenue predictability early-stage.

Cash Burn Rate

Pre-revenue biotechs burn cash. Key metric: cash runway = current cash / quarterly burn rate. Determines when next financing needed. Runway <12 months = equity dilution risk or strategic deal pressure.

Valuation Methodology

Primarily rNPV of pipeline. Sum probability-weighted NPV of each drug candidate. Enterprise Value = Cash on balance sheet + pipeline rNPV − debt. No earnings-based multiples apply.

Binary Events

Phase III readouts, FDA advisory committee votes, regulatory decisions. Stock can move 50%+ on a single event. Volatility is high; investors must understand trial success rates and competitive positioning.

Financing Cycles

Equity issuances, convertible notes, royalty financing, licensing deals. Dilution risk is constant. Successful biotech execs balance: reducing burn (disciplined R&D), raising capital (minimize dilution), and achieving clinical milestones (fund raises or partnerships).

Valuation Risk Biotech valuations are extremely sensitive to discount rate (small changes in r significantly impact rNPV), PoS estimates, and peak sales assumptions. Scenario analysis (base, upside, downside) is essential.

Medical Devices / MedTech

Capital Equipment & Recurring Consumables

Business Model: Develop, manufacture, sell medical devices and instruments. Ranges from high-value implants (orthopaedics, cardiac) to consumables (surgical tools, diagnostics).

Key Players

Medtronic, Abbott, Boston Scientific, Stryker, Smith & Nephew, Zimmer Biomet, Siemens Healthineers, GE Healthcare.

Revenue Model

Capital equipment + consumables + service contracts. Razor/blade model: place capital equipment cheaply (low margin), earn recurring revenue on consumables (high margin, 60-70% gross).

Margin Structure

Gross margin 60-70%, EBITDA margin 25-35%. Lower R&D intensity than pharma (6-10% of revenue). Manufacturing and supply chain are key cost drivers.

Organic Growth Drivers

Procedure volumes (demographics, clinical adoption), new product launches, emerging market expansion, ASP management. Typical organic growth 4-7% annually.

Regulatory Pathway

FDA 510(k) (predicate device, faster clearance) vs PMA (novel device, slower, requires clinical data). CE marking in Europe (MDR regulation tightening). Regulatory delays = revenue delays.

M&A Activity

MedTech is highly acquisitive. Bolt-on acquisitions for technology, product portfolio expansion, geographic reach. Typical entry multiples 15-25x EBITDA for quality targets.

MedTech — Recurring Revenue & Valuation

Predictability & Multiple Expansion

Recurring Revenue Ratio

Higher is better. Consumables and service contracts provide predictable revenue. Capital equipment is lumpy. Target recurring revenue ratio: >50% of total = high quality. Medtronic's ratio ~60%.

Hospital Procurement Dynamics

GPOs (Group Purchasing Organisations) and IDNs (Integrated Delivery Networks) consolidate buying power, pressuring ASPs. GPO contracts award to 1-2 vendors per product category, creating winner-take-most dynamics. ASP erosion = top-line pressure.

Innovation Cycles

New product launches critical for maintaining premium pricing. Clinical evidence and surgeon preference drive adoption. Companies must invest in R&D to stay competitive; launched innovation = >50% revenue growth driver.

Valuation Multiples

EV/EBITDA 15-25x for quality MedTech. Premium multiples for: high recurring revenue (>60%), market leadership, demographic tailwinds (aging population), innovation pipeline.

MedTech DCF Framework Revenue Growth = (Procedure Volume Growth + New Product Launch Impact + Emerging Market Expansion) × (1 − ASP Erosion %) EBITDA Margin = (Consumables Margin × Consumables %) + (Capital Equipment Margin × Capital %) + (Service Margin × Service %) Terminal Growth = 2-4% (mature company growth)

MedTech Valuation Example

Company: Cardiac device maker, current EBITDA $500M, organic growth 6%, 65% recurring revenue, $2B capex returns from new product, EV/EBITDA trading at 18x (industry median 16x premium for growth).

Fair Value: $500M × 18x = $9B EV. Premium justified: 6% organic growth, 65% recurring revenue, innovation pipeline, demographic tailwinds.

Healthcare Services

Fee-for-Service, Capitated, Consolidation

Sub-segments: Hospitals/clinics, primary care, dental chains, diagnostics/labs, rehabilitation, mental health, home health.

Revenue Model

Fee-for-service (volume × price per procedure) or capitated (fixed payment per patient per month, risk-bearing to provider). Mix of both: 60% FFS + 40% capitated typical for US health systems.

Key Metrics

Bed occupancy rate, revenue per admission, payer mix, same-facility growth, physician count, patient volumes. For diagnostics: tests per patient, price per test, volume growth.

Margin Drivers

Payer mix (private vs government), operational efficiency, capacity utilisation, labour costs (nurses, physicians largest cost). Private payer mix = 20-30% higher margins than government.

Regulatory Risk

Heavily regulated. NHS tariff system in UK, DRG-based reimbursement in many markets. Reimbursement rates set externally. Rate cuts directly impact margin and demand elasticity.

Consolidation Trend

Fragmented market being consolidated by PE and strategic acquirers. Roll-up strategies in dental (Smile Diagnostics), veterinary (VetPartners), ophthalmology. Entry multiples 6-10x EBITDA, exit 12-18x.

Reimbursement Risk NHS tariff changes or Medicare DRG cuts can materially reduce margins overnight. Monitor regulatory proposals; quantify revenue impact of potential rate cuts.

CROs & CDMOs

Contract Research & Manufacturing Infrastructure

CRO (Contract Research Organisation)

Outsourced clinical trial management and data analysis. Key players: IQVIA, Covance (LabCorp), PPD (Thermo Fisher), ICON, Syneos Health. Revenue: clinical trial services, regulatory consulting, data analytics.

CDMO (Contract Development & Manufacturing)

Outsourced drug manufacturing and scale-up. Key players: Lonza, Samsung Biologics, Catalent, WuXi, Recro Pharma. Revenue: manufacturing fees, capacity leasing, tech transfer.

Business Model & Visibility

Fee-for-service or milestone-based contracts. Revenue visibility through backlog and book-to-bill ratio (>1.0x = growing demand). Backlog typically 12-24 months forward.

Key Metrics

Backlog, book-to-bill ratio, revenue per employee, win rate (% of bidding), customer concentration (top 10 customers as % of revenue).

Growth Drivers

Pharma outsourcing trend (increasing % of R&D spend goes to CROs), biotech funding cycles (more biotech = more CRO demand), regulatory complexity (FDA requirements), pandemic demand surge (vaccine manufacturing).

Margin Profile

CRO EBITDA margins 20-30%. CDMO margins vary by complexity: small molecule 15-20%, biologics 25-35%. High variable costs; scale and efficiency critical.

CRO/CDMO Valuation

IQVIA Example: Largest CRO globally. Revenue ~$15B, EBITDA margin ~22%, EV/EBITDA 15-17x. Premium for scale, customer diversification, and biotech growth exposure.

Life Sciences Tools

Instruments, Reagents, Mission-Critical Recurring Revenue

Business Model: Selling instruments, reagents, consumables, and software to pharma, biotech, academic, and government research labs.

Key Players

Thermo Fisher, Danaher, Agilent, Waters, PerkinElmer, Illumina, 10x Genomics.

Razor/Blade Model

Instruments sold to labs (capital budget). Consumables (reagents, kits) are recurring and mission-critical (operating budget). Consumables are 60-70% of revenue. Instruments = customer acquisition; consumables = lifetime value.

Growth Drivers

R&D spending growth (pharma, biotech), government research funding (NIH grants), clinical diagnostics adoption, COVID pandemic demand surge for genomics and diagnostics.

Margin Structure

Gross margin 55-65%, EBITDA margin 25-35%. High operating leverage: consumables scale with existing customer base at high incremental margin.

Valuation

High-quality life sciences tools trade at 20-30x EBITDA. Premium for: recurring consumables revenue, mission-critical products, long product lifecycles (10+ years), market leadership in niche segments.

Life Sciences Tools Example

Thermo Fisher: Global leader in life sciences. Revenue ~$43B (2023), EBITDA margin ~35%, trading at ~24x EBITDA (~$20B EBITDA value). Premium justified: 60%+ recurring consumables revenue, global scale, mission-critical products.

Consumer Health & OTC

Stable, Branded, FMCG-Like Dynamics

Definition: Over-the-counter medicines and consumer wellness products. Recent spins: Haleon (from GSK, 2022), Kenvue (from J&J, 2023).

Revenue Model

Branded consumer products sold through retail (supermarkets, pharmacies, online). Closer to FMCG (Unilever, P&G) than pharma in operating model. Shelf space and marketing are critical.

Key Characteristics

Lower growth (2-4% organic) but very stable. No patent cliff risk (brands not patent-dependent). Strong brand loyalty (Paracetamol, ibuprofen, Listerine, Nicorette). Recurring revenue from repeat purchases.

Margin Profile

Gross margin 55-65%, EBITDA margin 20-28%. Lower than pharma due to retail distribution costs and promotional spending.

Valuation

EV/EBITDA 14-18x. Valued like consumer staples with a slight healthcare premium. Discount to big pharma multiples reflects slower growth and lower barriers to entry.

Recent M&A

Haleon IPO (GSK spinoff) priced at ~16x EBITDA (2023). Kenvue IPO (J&J spinoff) priced at ~15x EBITDA (2023). Both stable growth, high free cash flow, dividend payers.

Animal Health

Companion & Livestock, Secular Growth, No Reimbursement Risk

Definition: Veterinary pharmaceuticals and diagnostics. Key players: Zoetis (public, largest), Elanco, IDEXX, Dechra, Boehringer Ingelheim Animal Health.

Growth Drivers

Pet ownership growth (secular trend), humanisation of pets (owners spending >$20B/year in US on pet care), livestock health demand from food production, antibiotic alternatives (regulatory ban on growth-promoting antibiotics).

Companion vs Livestock

Companion animal is higher growth (5-8%) and higher margin. Livestock is cyclical (linked to commodity prices and farming economics). Zoetis: 60% companion, 40% livestock.

No Reimbursement Risk

Pet owners pay out of pocket (no insurance for most). Minimal government pricing intervention. Price increases easier to implement than human healthcare. Pricing power advantage.

Valuation

Premium multiples 20-30x EBITDA (vs 15-25x for pharma). Premium reflects: durable growth, no reimbursement risk, secular tailwinds, defensive characteristics (recession-resistant pet spending).

Animal Health Valuation

Zoetis: Listed 2013, ~$20B market cap. Revenue ~$8B, EBITDA margin ~33%, trading at ~25x EBITDA. Premium justified: 6% organic growth, 60% high-margin companion animal, emerging market expansion, no reimbursement risk.

Genomics & Precision Medicine

Emerging, Early-Stage, High Uncertainty

Definition: Genomic sequencing, gene therapy, cell therapy, personalised medicine. Rapidly expanding segment with transformative potential.

Key Players

Illumina (sequencing leader), 10x Genomics, CRISPR Therapeutics, Editas Medicine, BioNTech, Moderna, Velo3D.

Revenue Models

Instrument + consumables (Illumina), product sales (approved therapies like Zolgensma gene therapy $3M+), licensing/milestone (early-stage), diagnostic testing (companion diagnostics).

Valuation Challenges

Many companies pre-revenue or early-revenue. Valued on TAM-based analysis, pipeline rNPV, and strategic premium (big pharma buying for platform capability). Discount rates 15-20% (high execution risk).

Gene Therapy Pricing

One-time curative therapies priced at $1-3M+ per patient. Reimbursement and payer acceptance is critical risk. Zolgensma (spinal muscular atrophy): $3.5M per patient one-time therapy. Payers negotiating outcome-based pricing (refund if therapy fails).

Strategic Premium

Pharma companies pay 2-3x revenue multiples for genomics platforms due to optionality value (potential to transform drug development pipeline). This creates valuation disconnects with traditional metrics.

Emerging Sector Risk Genomics is high-growth but early-stage. Regulatory frameworks evolving (FDA guidance on gene therapy, EMA standards). Patent landscape contested (CRISPR patent disputes). Technology risk (off-target effects, manufacturing scale). Assume 15-20% failure rates even for late-stage assets.

PART III — VALUATION FRAMEWORKS

Pharma Valuation

Sum-of-the-Parts + Risk-Adjusted NPV

Standard Pharma Valuation Framework: Mature products (DCF or multiples) + pipeline (rNPV) + net cash = enterprise value.

Sum-of-Parts Approach

Value each drug franchise separately. Declining products get lower multiples (e.g., 8-12x EBITDA). Growing/peak products 15-25x EBITDA. Sum franchises + pipeline rNPV + net cash = equity value.

rNPV Methodology

For each pipeline asset: estimate peak sales, market ramp profile (slow launch → peak over 5-7 years), probability of success by stage, cost assumptions, discount rate (10-12% for pharma). Calculate NPV of annual cash flows. Discount further for PoS. Sum all assets = pipeline rNPV.

Terminal Value Critical

For pharma, use caution with terminal value. Patents expire, drugs don't grow forever. Use finite commercial life (8-12 years from launch, not perpetuity). Terminal value = Year N EBITDA × exit multiple (8-12x), not Gordon growth model.

Comparable Transactions

Look at licensing deals and acquisitions for similar-stage assets in the same therapeutic area. E.g., Roche paid $2.4B for in-Phase III immunotherapy = ~$1.5-2B per Phase III asset in oncology depending on peak sales assumptions.

Pharma Sum-of-Parts DCF Mature Revenue (R) × (1 − erosion) / (1 + WACC)^t + Pipeline rNPV + Net Cash = Equity Value

Pharma Valuation Worked Example

Company: AZ-like company, $40B revenue, $50B EBITDA, top 5 drugs ~50% of revenue with LOE 3-7 years, Phase III pipeline $50B rNPV (prob-weighted), $10B net cash.

Valuation: DCF on mature revenue (assuming -30% cliff in years 4-6) + $50B pipeline rNPV + $10B cash = ~$400-500B EV (assuming terminal value and timing assumptions).

MedTech & Services Valuation

EV/EBITDA Multiples & Roll-Up Economics

MedTech Multiples

EV/EBITDA primary metric. 15-25x for quality names (Medtronic, Boston Scientific, Stryker). Premium for: market leadership, recurring revenue >60%, innovation pipeline, demographic tailwinds (aging), emerging market exposure.

Healthcare Services Multiples

EV/EBITDA 8-15x. Lower than MedTech due to: labour intensity, lower barriers to entry, regulatory risk, lower growth potential. Hospital operators 8-12x. Diagnostics companies 12-15x (higher recurring revenue).

Roll-Up Valuation Model

PE-backed healthcare services play (dental, vet, ophthalmology): buy single units at 6-8x EBITDA. Build platform (consolidate, integrate, improve operations). Exit platform at 12-15x EBITDA. Arbitrage = 50-75% return.

DCF Framework

Project: procedure volumes (% growth annually), pricing power (ASP change), new product launches (% revenue from new launches), margin expansion (scale), working capital needs, capex requirements. Terminal growth 2-4%.

MedTech DCF Revenue = Base Year × (1 + Organic Growth %) × (1 − ASP Erosion %) × New Product Uplift EBITDA = Revenue × Adj. EBITDA Margin (accounting for FX, mix shift) FCF = EBITDA − D&A − Capex − Working Capital Change − Taxes Terminal Value = Year N FCF × (1 + g) / (WACC − g), where g = 2-4%

MedTech Roll-Up Economics

Scenario: PE firm buys dental platform: entry at 5x EBITDA ($50M EBITDA = $250M entry price). Add 3 bolt-on acquisitions at 6x EBITDA each ($150M + $100M + $75M acquisitions). Build platform EBITDA to $150M through synergies and growth. Exit at 12x EBITDA ($1.8B). Invested capital $575M, exit $1.8B, 3.1x MoIC.

Biotech Valuation

rNPV, Option Value & M&A Premiums

Pre-Revenue Biotech

Sum of rNPV of pipeline + cash − debt = equity value. No earnings-based multiples applicable. Valuation = development-stage sum-of-parts.

Key rNPV Assumptions

Peak sales (derived from addressable patient population × market share × price), probability of success (by stage), time to market (when cash hits), discount rate (12-15% for biotech reflecting execution risk).

Discount Rate Sensitivity

Small changes in discount rate materially change rNPV. Shifting discount rate from 10% to 15% can reduce NPV 20-30%. Sensitivity analysis mandatory: show base, upside, downside scenarios.

Option Value

Even failed drugs have optionality (new indications, combination approaches, platform technology value). Don't write assets to zero; include tail value. Platform value often >50% of sum of individual drugs.

M&A Premium & Pharma Acquisitions

Pharma acquires biotech at significant premiums (40-100%+) to market price for de-risked late-stage assets. Incentive: in-license drug at Phase III (55-60% PoS) vs develop internally (10% PoS). Pharma pays up for risk reduction.

Biotech rNPV Valuation EV = Σ [PoS × NPV(Peak Sales × Market Share × Commercial Life / (1 + r)^t)] − Dev Costs + Cash − Debt where PoS = cumulative probability from current stage to approval r = 12-15% (biotech discount rate) t = time to launch

Biotech Valuation Sensitivity

Scenario: Biotech with Phase III drug, peak sales $2B, 55% PoS, 4 years to launch, 10-year commercial life, $150M dev costs remaining, $200M cash, $0 debt.

Base (r=12%): rNPV ≈ $4.2B, EV ≈ $4.25B (55% × ~$7.8B PV − $150M + $200M)

Upside (r=10%, PoS 65%): rNPV ≈ $6B+

Downside (r=15%, PoS 40%): rNPV ≈ $2B

Insight: Wide valuation range based on discount rate and PoS. Pharma buyer offering $5-6B premium justified if they believe >55% PoS and can integrate into platform.

Healthcare M&A Dynamics

Deal Drivers, Multiples, Regulatory Considerations

Pharma M&A

Driven by patent cliff replacement. Pharma buys biotech for pipeline. Large deals ($10B+) for transformative platform acquisitions (Roche → Genentech $47B; Pfizer → Hospira $17B; AZ → Rixibixi stage immunotherapy). Smaller bolt-ons ($1-5B) for individual drug assets. Strategic premiums 40-100%+.

MedTech M&A

Highly acquisitive sector. Bolt-on acquisitions for technology, product line expansion, geographic reach. Medtronic, Abbott, Boston Scientific constantly acquiring. Typical multiples: 15-25x EBITDA for quality targets. Integration focus: cross-selling, eliminating redundant SG&A, supply chain optimization.

Healthcare Services M&A

PE-driven consolidation. Buy-and-build in fragmented segments (dental, diagnostic labs, optometry, mental health). Entry multiples 6-10x EBITDA (consolidation discount), exit 12-18x EBITDA (platform premium). Multiple arbitrage is the value creation lever.

Regulatory Approval Risk

Antitrust review for large pharma mergers (FTC/CMA scrutiny). CFIUS review for cross-border deals involving sensitive healthcare assets (genomics, diagnostics, data). Deal certainty: 85-90% for <$5B, 70-80% for >$10B.

Recent Mega-Deals (2022-2024)

Roche → Exseris ($2.7B, diagnostics), Bristol Myers → Mirati ($4.8B, oncology biotech), Eli Lilly → Loxo ($8B+, oncology), Novo Nordisk → Heart Therapeutics ($300M, cardiometabolic), Zimmer Biomet → LivaNova ($4.3B, cardiac), Sandoz IPO (ex-Novartis generics) valued at $10B+.

M&A Deal Value Estimation Base Valuation (DCF or trading multiples) + Strategic Premium (30-80% for synergy value) + Control Premium (30-50% for 100% acquisition vs. minority stake) = Acquisition Price

PART IV — DILIGENCE & RED FLAGS

Patent Cliff & Pipeline Risk

Quantification & Stress Testing

The Fundamental Question: Can the company replace revenue from expiring products?

Patent Cliff Quantification

List every product >5% of revenue: name, current revenue, LOE date, expected erosion curve (30-90% depending on small-molecule vs. biologic). Sum = total revenue at risk by year. Example: AZ 2023 cliff: $6B at risk 2024-2027 on mature portfolio.

Pipeline Quality Assessment

For each Phase III asset: stage, unmet medical need, competitive landscape (how many competitors?), differentiation (better efficacy, safety, convenience?). A large Phase III pipeline can be worthless if drugs target crowded indications with existing therapies.

R&D Productivity

Compare R&D spend (% of revenue) to approved drugs approved. Declining productivity = red flag. Example: if Company A spends 20% of revenue on R&D but hasn't approved a drug in 5 years, productivity is declining. Contrast with Company B (18% spend, 1 approval annually).

Peak Sales Credibility

For pipeline assets, check if peak sales estimates are credible. Addressable market size × estimated market share. Example: small-cell lung cancer is ~50K patients annually in US. If a company estimates peak sales of $5B for an SCLC drug, they're assuming ~$100K per patient per year pricing (possible but aggressive). Sanity-check numbers.

Patent Cliff Red Flag

MAJOR RED FLAG: A pharma company with >30% of revenue at risk from patent cliffs in the next 5 years, with NO Phase III assets, and R&D productivity declining = structurally challenged. Even with M&A, this company is a value trap.

Patent Cliff Diligence Case

GSK 2023: Top drugs: Shingrix (vaccines), Nucala (asthma), Trelegy (respiratory). Most patents extend to 2027-2032. Phase III pipeline includes ~10 late-stage assets (immunology, oncology, vaccines). Conclusion: managed cliff risk through both new product pipeline and diversification. Not a red flag.

Reimbursement & Pricing Risk

Regulatory Headwinds & Market Dynamics

Government Pricing Pressure

Most developed markets impose drug pricing controls. UK: NICE HTA (health technology assessment) determines price/access. Europe: reference pricing (many countries tied to Germany/France benchmarks). US: IRA allows Medicare to negotiate prices on certain drugs (implemented 2024). Price cuts = margin pressure.

IRA (Inflation Reduction Act) Impact

Allows Medicare to negotiate prices on high-revenue drugs without generics/biosimilars. List includes: Enbrel, Imbruvica, Januvia, Stelara, Xarelto. Price cuts 20-55% expected for first negotiation wave (2024). Revenue impact material for affected companies.

NICE HTA Assessment Risk

UK/EU drug access determined by cost-effectiveness vs. existing therapies. NICE uses £30K per QALY willingness-to-pay threshold (though flexible). Negative NICE opinion = reimbursement denial in UK. Examples: some drugs approved in US rejected by NICE (too expensive, insufficient clinical benefit).

MedTech Reimbursement

Hospital budgets are finite. New devices must demonstrate clinical AND economic value (cost per procedure vs. existing standard). Reimbursement pressure: hospitals consolidating (GPOs), negotiating lower prices. ASP erosion 1-3% annually typical.

Healthcare Services Reimbursement

NHS tariff changes directly impact revenue per procedure. Example: NHS reduced hip replacement tariff 3% in 2022 = direct margin compression for hospital operators. Regulatory event risk.

Pricing Risk Stress Testing

Scenario Analysis Required: Assume 10-15% price reduction from IRA/payer negotiation for key drugs. Model EBITDA impact. Example: $3B drug at 40% EBITDA margin, 15% price cut = $180M EBITDA loss (~5% of total for integrated pharma).

Clinical & Regulatory Risk

Binary Events, Safety, Manufacturing

Phase III Failure

The most expensive failure. $200M-500M trial cost wasted. Stock impact for biotech: 50-80% decline possible. For integrated pharma, one Phase III failure = 5-15% equity value impact. Risk appetite matters; clinical stage assessment is paramount.

Regulatory Risk

FDA Complete Response Letter (CRL) = rejection or request for more data (not approval). EMA CHMP negative opinion. Both result in delayed launches or resubmissions, affecting valuation timing assumptions.

Post-Marketing Safety

Black box warnings, REMS (Risk Evaluation & Mitigation Strategies), label narrowing, or market withdrawals can destroy drug value years after approval. Example: Avandia (diabetes drug) faced restrictions post-approval, reducing peak sales 50-70%.

Manufacturing Risk

Drug shortages (quality control failures), FDA warning letters, consent decrees = supply disruption and revenue loss. Example: Biohaven faced manufacturing issues delaying launch of key psychiatric drug.

Regulatory Track Record

Review management's FDA approval rate, cycle times, and any warning letters/Form 483 observations from FDA inspections. Track record is predictive of future execution risk.

Clinical Risk Quantification

Phase III Asset Valuation: Peak sales $2B, 55% PoS (industry average Phase III). If trial fails (45% probability), stock could decline 60%. Implied expected value adjustment already captured in 55% probability. But scenario analysis shows downside to $400-500M value if trial fails.

Healthcare Diligence Checklist

Essential Questions for IB Deal Work

Revenue Concentration: Top drug as % of total? Top 5 drugs? Industry risk <50% from single drug.
Patent Cliff Timeline: Revenue at risk over next 5 years? Estimate % erosion by year. Compare to pipeline value.
Pipeline Quality: Number and stage of assets? Probability-weighted value? Realistic peak sales assumptions? Competitive landscape?
R&D Productivity: R&D spend (% revenue) vs. approved drugs (per $10B spent)? Trend improving or declining?
Reimbursement Environment: Payer mix (private vs. govt)? Pricing trends? IRA, NICE, NHS tariff impacts? Risk of cuts?
Competitive Landscape: Peers per therapy area? Market share trends? Generic/biosimilar threats? Differentiation of pipeline?
Regulatory History: FDA approval rate, cycle times, warning letters? Management track record?
Geographic Diversification: % US revenue (highest pricing, IRA risk)? Europe, Japan, emerging markets? FX exposure?
Cash Generation & Capital Allocation: FCF trends? Dividend sustainability? M&A capacity? Share buybacks vs. growth investing?
Management Track Record: M&A integration success? Pipeline delivery history? Strategic vision clarity?

Sub-Sector Comparison

Key Metrics Across Healthcare Segments

Big Pharma

Gross Margin: 70-80%

EBITDA Margin: 30-40%

EV/EBITDA: 12-16x

Growth: 2-5%

Primary Risk: Patent cliff

Revenue Model: Drug sales, royalties

M&A Activity: High (bolt-ons, pipeline)

Biotech

Gross Margin: N/A (pre-revenue)

EBITDA Margin: Negative

Valuation: rNPV-based

Growth: High (if successful)

Primary Risk: Clinical/regulatory

Revenue Model: Licensing, milestones, royalties

M&A Activity: Very high (acquisition target)

MedTech

Gross Margin: 60-70%

EBITDA Margin: 25-35%

EV/EBITDA: 15-25x

Growth: 4-7%

Primary Risk: ASP erosion, competition

Revenue Model: Equipment + consumables

M&A Activity: Very high (bolt-ons)

Healthcare Services

Gross Margin: 25-40%

EBITDA Margin: 15-25%

EV/EBITDA: 8-15x

Growth: 2-4%

Primary Risk: Reimbursement cuts

Revenue Model: FFS, capitated

M&A Activity: High (PE roll-ups)

Life Sciences Tools

Gross Margin: 55-65%

EBITDA Margin: 25-35%

EV/EBITDA: 20-30x

Growth: 6-10%

Primary Risk: R&D spending cycles

Revenue Model: Equipment + consumables

M&A Activity: High (tuck-ins)

CRO/CDMO

Gross Margin: 40-50%

EBITDA Margin: 20-30%

EV/EBITDA: 12-18x

Growth: 5-8%

Primary Risk: Customer concentration

Revenue Model: Fee-for-service, backlog

M&A Activity: Moderate (capacity deals)

PART V — APPENDIX

London Healthcare IB Landscape

Teams, Deal Types, Market Leadership

Major Investment Banking Teams

Goldman Sachs, Morgan Stanley, J.P. Morgan, Lazard, Centerview, Jefferies (especially strong in healthcare M&A), SVB Securities (focused on biotech/life sciences), Leerink (pure biotech play now part of Mizuho).

Deal Types

Pharma M&A (large-cap consolidation, patent cliff replacement), biotech licensing/acquisitions (pharma buying R&D), MedTech bolt-ons, healthcare services PE buyouts and roll-ups, biotech IPOs (frequent exit strategy), clinical trial services consolidation.

Market Leadership

Healthcare is one of the most active M&A sectors globally. 2023: $126B healthcare M&A (Dealogic). London teams competing for: pharma advisory, biotech fundraising, MedTech bolt-on support, PE healthcare deals, public company advisory (strategic options, capital allocation).

Interview Themes

Patent cliff management, pipeline valuation, comparable transaction multiples, M&A synergy analysis, healthcare sector dynamics (pricing pressure, consolidation, regulation), deal structuring (earn-outs for biotech, etc.), regulatory approval risk assessment.

Recent Healthcare M&A (London IB Active)

Deals 2023-2024: Roche → Carmot therapeutics (obesity/diabetes, preclinical), Novo Nordisk → Presco (early-stage obesity), Eli Lilly → Loxo Oncology ($8B), Sanofi → Fvax (vaccines platform), Takeda → Dompe ($380M, rare disease). London IB teams advised on numerous bolt-on MedTech acquisitions and healthcare services PE deals.

Healthcare Special Complete

Key Takeaways & Framework Mastery

From patent cliffs to pipeline rNPV, from MedTech razor/blade models to PE-backed healthcare services roll-ups — the healthcare sector is complex but the frameworks are consistent.

Mastery Requirements:

Quantify patent cliff impact: revenue at risk, erosion curves, timing of generic/biosimilar entry.
Probability-weight pipeline assets: assess PoS by stage, peak sales credibility, competitive positioning, time to market.
Value recurring revenue: MedTech consumables, life sciences tools, healthcare services loyalty = stability and margin upside.
Stress test reimbursement: model price cuts from IRA, NICE, payer negotiation. Impact to EBITDA and valuation.
M&A arbitrage: pharma acquiring biotech at 40-100% premium for risk reduction; PE rolling up fragmented services at 2-3x MoIC; MedTech bolt-ons for synergy.
Regulatory risk awareness: Phase III failure, FDA response times, manufacturing risk, post-marketing safety — all binary, all material.

Interview Closing:

"Value the pipeline. Stress-test the patent cliff. Respect the regulator."

Download Healthcare Cram Sheet

PDF — 5 pages — Sector-specific reference

Chapter 16 complete. Healthcare sector mastery = IB edge.